137 results on '"Le Calloch, Ronan"'
Search Results
2. Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies
3. Faire vivre et grandir une communauté de chefs de service : acte 2 en hématologie
4. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
5. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm
6. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
7. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
8. Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study
9. Eculizumab, a real-life successful treatment for refractory cold agglutinin–mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders
10. P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
11. Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
12. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study
13. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
14. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA
15. The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
16. Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study
17. Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
18. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy
19. Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma
20. Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study
21. Fungal arthritis of the hip in patient with aplastic anaemia
22. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
23. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study.
24. Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis
25. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study
26. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
27. Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature
28. Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies
29. Major Role for TRPV1 and InsP3R in PAR2-Elicited Inflammatory Mediator Production in Differentiated Human Keratinocytes
30. Une cause rare d’hémorragie méningée
31. Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)
32. Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation
33. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
34. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
35. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study
36. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
37. Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
38. Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry
39. Hémophilie A acquise chez le sujet âgé : deux observations cliniques.
40. Mantle cells lymphoma: standards and news
41. Place du ruxolitinib dans la polyglobulie de Vaquez, résultats de l’étude internationale d’enregistrement (RESPONSE) : bientôt une autorisation de mise sur le marché en France !
42. Mutations de la calréticuline dans la thrombocytémie essentielle : le point à un an
43. The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
44. Incidence and Localization of Vascular Events in a Well Characterized Cohort of 477 Patients with Myeloproliferative Neoplasms
45. Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT)
46. [Nurturing and growing a community of department heads: Act 2 in haematology].
47. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
48. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
49. Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature.
50. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.